Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology. Hazenberg BP, et al. Among authors: wijermans pw. Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6. Haematologica. 2015. PMID: 25661441 Free PMC article. Clinical Trial.
Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW. Lokhorst HM, et al. Among authors: wijermans pw. Br J Haematol. 1996 Jan;92(1):44-8. doi: 10.1046/j.1365-2141.1996.00306.x. Br J Haematol. 1996. PMID: 8562409 Clinical Trial.
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Löwenberg B, et al. Blood. 1997 Oct 15;90(8):2952-61. Blood. 1997. PMID: 9376575 Free article. Clinical Trial.
[Multiple myeloma; treatment in the year 1998].
Lokhorst HM, Sonneveld P, Wijermans PW, Segeren CM. Lokhorst HM, et al. Among authors: wijermans pw. Ned Tijdschr Geneeskd. 1998 Jul 11;142(28):1596-602. Ned Tijdschr Geneeskd. 1998. PMID: 9763840 Review. Dutch.
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW. Lokhorst HM, et al. Among authors: wijermans pw. Bone Marrow Transplant. 1999 Feb;23(4):317-22. doi: 10.1038/sj.bmt.1701574. Bone Marrow Transplant. 1999. PMID: 10100574 Clinical Trial.
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Segeren CM, et al. Among authors: wijermans pw. Br J Haematol. 1999 Apr;105(1):127-30. Br J Haematol. 1999. PMID: 10233375 Free article. Clinical Trial.
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Vellenga E, van Putten WL, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Jonkhoff AR, Huijgens PC, Verdonck LF, van der Lelie J, Schouten HC, Gmür J, Wijermans P, Gratwohl A, Hess U, Fey MF, Löwenberg B. Vellenga E, et al. Bone Marrow Transplant. 1999 Jun;23(12):1279-82. doi: 10.1038/sj.bmt.1701799. Bone Marrow Transplant. 1999. PMID: 10414916 Clinical Trial.
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P, Wijermans PW, van der Lelie J, van Putten WL, Löwenberg B. Ossenkoppele GJ, et al. Among authors: wijermans pw. Leukemia. 1999 Aug;13(8):1207-13. doi: 10.1038/sj.leu.2401478. Leukemia. 1999. PMID: 10450748 Clinical Trial.
192 results